Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Discovery
De Novo and partner announce successful completion of GPCR Library
August 6th, 2004
De Novo Pharmaceuticals, Ltd., the Cambridge, U.K.-based computational drug-design company, announced its collaboration with Peakdale Molecular has resulted in the successful launch of a new range of Peakexplorer screening compound libraries designed with the help of De Novo Pharmaceuticals' computational drug-design platform SkelGen. The first library is focused on G-Protein Coupled Receptors (GPCR) and contains over 1000 well-characterized, highly diverse proprietary drug-like compounds. Peakexplorer G1 was created through a process that combines De Novo's modeling, computational design, and virtual screening with Peakdale's proprietary chemistry...
Source: Genomics & Genetics Weekly (2004-08-06)
|
